Rock Springs Capital Management LP has $6.80 million stock holdings in Omada Health, Inc. $OMDA. July 28, 2026 Key points. * Rock Springs Capital Management cut its Omada Health position by 26.9%, selling 199,000 shares and retaining 541,000 shares worth approximately $6.8 million, or 0.91% of the company. * Several institutional investors initiated new positions in Omada during the second quarter, while company insiders sold 193,462 shares worth about $3.93 million in the latest quarter. * Omada reported quarterly revenue of $78.05 million and an adjusted loss of $0.05 per share, beating expectations. Analysts maintain a "Moderate Buy" consensus, with an average price target of $24.33 versus the stock's $20.58 opening price. * MarketBeat previews top five stocks to own in August. Rock Springs Capital Management LP decreased its position in Omada Health, Inc. (NASDAQ:OMDA - Free Report) by 26.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 541,000 shares of the company's stock after selling 199,000 shares during the quarter. Rock Springs Capital Management LP owned approximately 0.91% of Omada Health worth $6,800,000 as of its most recent SEC filing. Several other large investors have also modified their holdings of OMDA. Geode Capital Management LLC acquired a new position in Omada Health in the 2nd quarter valued at $637,000. Walleye Capital LLC acquired a new position in Omada Health during the 2nd quarter worth $458,000. Ilex Capital Partners UK LLP bought a new stake in Omada Health during the second quarter valued at about $201,000. Soros Fund Management LLC bought a new stake in Omada Health during the second quarter valued at about $640,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Omada Health in the second quarter valued at about $32,000. Insider buying and selling at Omada Health. In other news, CEO Sean P. Duffy sold 25,886 shares of Omada Health stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $22.68, for a total transaction of $587,094.48. Following the sale, the chief executive officer owned 411,861 shares of the company's stock, valued at approximately $9,341,007.48. This trade represents a 5.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Craig Gracey sold 6,894 shares of the business's stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $17.42, for a total value of $120,093.48. Following the sale, the chief accounting officer owned 9,191 shares in the company, valued at approximately $160,107.22. This represents a 42.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 193,462 shares of company stock valued at $3,927,425 in the last quarter. Corporate insiders own 6.38% of the company's stock. Omada Health stock performance. NASDAQ:OMDA opened at $20.58 on Tuesday. The firm's 50-day moving average is $19.72 and its 200-day moving average is $15.93. The company has a market cap of $1.22 billion and a price-to-earnings ratio of -76.22. Omada Health, Inc. has a 52-week low of $10.28 and a 52-week high of $26.92. Omada Health (NASDAQ:OMDA - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The business had revenue of $78.05 million during the quarter. Equities analysts predict that Omada Health, Inc. will post -0.01 EPS for the current year. Analyst ratings changes. A number of equities analysts have recently commented on OMDA shares. The Goldman Sachs Group reissued a "buy" rating on shares of Omada Health in a research report on Friday, May 8th. Barclays raised their target price on Omada Health from $18.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, May 8th. BTIG Research began coverage on Omada Health in a research report on Friday, July 17th. They issued a "buy" rating and a $30.00 price target on the stock. Citigroup reiterated an "outperform" rating on shares of Omada Health in a report on Monday, July 20th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of Omada Health in a research report on Friday, May 8th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $24.33. Omada Health company profile. Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching. In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management. Want to see what other hedge funds are holding OMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omada Health, Inc. (NASDAQ:OMDA - Free Report). This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Omada Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list. While Omada Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Omada Health to host its first Investor Day on September 10, 2026. SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) - Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will host its first Investor Day on Thursday, September 10, 2026. The half-day, in-person event will take place in New York City and begin at 1:00 pm EDT. During the session, investors will hear directly from leaders about Omada's vision, strategy, and long-term growth plans. The program will be accessible via a live webcast at https://investors.omadahealth.com/news-events/events. A replay of the program and related materials will also be available at the same link following the event. About Omada Health Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits-where health is won or lost-at the center of care. Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada's virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com. Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on its current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, macroeconomic and industry conditions and other factors. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of its control. Its actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause its actual results and financial condition to differ materially from those indicated in the forward-looking statements include, but are not limited to, the following: its limited operating history and ability to manage its growth effectively; its history of net losses and ability to maintain profitability; the ability of its programs to achieve and maintain market acceptance; changes in the healthcare industry and competition; the growth and success of its customers and channel partners; the number of individuals covered by its programs and the number of its programs covered by its customers; the level of member engagement in its programs; its ability to maintain and grow customer and channel partner relationships; concentration of a substantial portion of its sales among a limited number of customers and channel partners; its ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners; its ability to increase the size of its organization; its dependence on a limited number of third-party suppliers; the impact of seasonality on its financial results; its ability to achieve widespread brand awareness and the impact of any negative media coverage; its ability to develop and release new programs and services; cybersecurity threats; its dependence on the interoperability of its programs and connected devices with third-party devices, operating systems and applications; changes in laws or regulations or the implementation of existing laws and regulations; compliance with privacy and security laws and regulations; its and its affiliated professional entities' compliance with healthcare regulatory laws; any modification in U.S. Food and Drug Administration enforcement policies; its dependence on its relationships with affiliated professional entities; and other risk factors identified in its filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. All forward-looking statements in this press release are based only on information currently available to GovCloud Network and speak only as of the date on which they are made. GovCloud Network undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required under applicable law.

Amidst strong US market performance, with a 28% annual gain and projected 17% earnings growth, several stocks appear undervalued based on cash flow analysis. The market has risen 1.8% over the past week. Alkami Technology trades at $17.59, significantly below its estimated fair value of $30.58 based on discounted cash flow analysis. The cloud-based digital platform provider expects profitability within three years, with substantial earnings growth projected annually. Analysts forecast a 23% stock price increase, though recent insider selling and slower revenue growth warrant caution. Omada Health trades at $17.82, well below its estimated value of $28.24. The virtual care provider anticipates profitability within three years, with earnings growth forecast at 95.77% annually. Recent partnerships and strong quarterly results show revenue growth and reduced losses.